Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,145 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Urogenital Diseases Clear all
Recruiting Not applicable Interventional

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

NCT06516653
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
VasQ, Arteriovenous fistula creation for dialysis vascular access
Device · Procedure
Lead sponsor
Laminate Medical Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Long Beach, California • Sarasota, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00003345
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, irinotecan hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Treatment of Depression in ESRD Patients on Dialysis

NCT00618475
View directory record Official record
Conditions
End Stage Renal Disease, Depression
Interventions
Cognitive behavioral therapy
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated Phase 4 Interventional Results available

Double-Blind Placebo-Controlled CIN Trial

NCT02467075
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Iopamidol 300 (Contrast), Placebo (Normal Saline)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 1, 2026, 2:27 PM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

NCT01450657
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics/Renadyl
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 4 Interventional

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

NCT00224081
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis
Interventions
Sodium ferric gluconate,
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
29
States / cities
Bakersfield, California • Glendale, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 1, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep Disturbances as a Non-Traditional Risk Factor in Chronic Kidney Disease- University of Illinois

NCT00817492
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
21 Years to 74 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Chronic Kidney Disease Antidepressant Sertraline Trial

NCT00946998
View directory record Official record
Conditions
Chronic Kidney Disease, Depression
Interventions
Sertraline, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women

NCT03267563
View directory record Official record
Conditions
Depression, Postpartum
Interventions
EIAU, LICF, HICF
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

The Effect of Human Recombinant Erythropoietin in Acute Renal Failure

NCT03102021
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
erythropoietin, saline
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)

NCT07232602
View directory record Official record
Conditions
Bladder Cancer
Interventions
MK-3120, EV, Pembrolizumab, Rescue Medication
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
San Francisco, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Not applicable Interventional

Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization

NCT02287701
View directory record Official record
Conditions
Bladder Cancer
Interventions
PET/MRI
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated Not applicable Interventional

A Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty

NCT02634619
View directory record Official record
Conditions
Urethral Stricture
Interventions
Ventral buccal mucosa onlay urethroplasty, Dorsal buccal mucosa onlay urethroplasty
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 1, 2026, 2:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Self-collected Swabs for HPV Testing in 18-24 Year Old Women

NCT01101828
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 24 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients

NCT01689636
View directory record Official record
Conditions
Ovarian Cancer, Healthy Volunteers
Interventions
Tc 99m EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 2 Interventional

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT07285044
View directory record Official record
Conditions
Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions
Cancer Therapeutic Procedure, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

NCT03436745
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Zolpidem, ECG
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Not listed Not applicable Interventional

Impact of Early Renal Involvement on the Development of Severe In-hospital Renal Failure

NCT00806039
View directory record Official record
Conditions
Kidney Failure, Acute, Renal Insufficiency, Acute, Kidney Failure, Renal Insufficiency
Interventions
Early Renal Involvement
Other
Lead sponsor
Saint Louis VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 16, 2009 · Synced Oct 1, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional Results available

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

NCT00089128
View directory record Official record
Conditions
Bladder Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 1, 2026, 2:27 PM EDT
Active, not recruiting No phase listed Observational

A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer

NCT03193528
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Rochester, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 1, 2026, 2:27 PM EDT
Terminated No phase listed Observational

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00957736
View directory record Official record
Conditions
Cancer
Interventions
polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 1, 2026, 2:27 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

NCT02521844
View directory record Official record
Conditions
Solid Tumors
Interventions
ETC-1922159, Pembrolizumab
Drug
Lead sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Government
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Tucson, Arizona • Orange, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 1, 2026, 2:27 PM EDT